Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (631-640 of 759) with videos related to

Pageof 76
Sort By:
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|June 15, 2026
Design and Rationale of the REVEAL PET Study: A Study of <sup>124</sup>I-evuzamitide to Diagnose Cardiac AmyloidosisSharmila Dorbala, Mathew S Maurer, Sarah A M Cuddy, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood Cancer Journal|May 8, 2020
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?M Hasib Sidiqi, Mohammed Aljama, Shaji K Kumar, et al.
Blood Advances|January 27, 2026
American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain AmyloidosisVishal Kukreti, Matthew D Seftel, Maria Adela Aguirre, et al.
Mayo Clinic Proceedings|February 17, 2019
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified TypingEli Muchtar, Morie A Gertz, Robert A Kyle, et al.
Pageof 76

Showing results (631-640 of 759) with videos related to

Sort By:
Pageof 76
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|June 15, 2026
Design and Rationale of the REVEAL PET Study: A Study of <sup>124</sup>I-evuzamitide to Diagnose Cardiac AmyloidosisSharmila Dorbala, Mathew S Maurer, Sarah A M Cuddy, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood Cancer Journal|May 8, 2020
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?M Hasib Sidiqi, Mohammed Aljama, Shaji K Kumar, et al.
Blood Advances|January 27, 2026
American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain AmyloidosisVishal Kukreti, Matthew D Seftel, Maria Adela Aguirre, et al.
Mayo Clinic Proceedings|February 17, 2019
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified TypingEli Muchtar, Morie A Gertz, Robert A Kyle, et al.
Pageof 76